检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:李朋军[1] 沈伟哉[1] 叶文才[2] 张冬梅[2] 孙艳[3]
机构地区:[1]暨南大学医学院,广东广州510632 [2]暨南大学药学院,广东广州510632 [3]广东药学院生命科学与生物制药学院,广东广州510006
出 处:《中国病理生理杂志》2011年第5期838-842,共5页Chinese Journal of Pathophysiology
基 金:国家自然科学基金资助项目(No.81000923);广东省医学科学技术研究基金资助项目(No.B2009117);广东高校优秀青年创新人才培育资助项目(No.2009400)
摘 要:目的:初步探讨点地梅提取物saxifragifolin B体外抗实体瘤活性及其作用机制。方法:Saxifragifo-lin B作用于体外培养的人肝癌细胞BEL-7402、肺癌细胞A549和胃癌细胞SGC7901。光镜下观察肿瘤细胞形态学变化;AO/EB双染法观察细胞死亡;MTT法检测细胞增殖水平,计算IC50;流式细胞术检测细胞凋亡和坏死。结果:Saxifragifolin B诱导3种实体瘤细胞出现凋亡样和坏死样改变。Saxifragifolin B以浓度依赖的方式抑制肿瘤生长,作用24 h IC50分别为13.13μmol/L、9.61μmol/L和11.64μmol/L。Saxifragifolin B可以诱导肿瘤细胞凋亡和坏死。结论:点地梅提取物saxifragifolin B具有抗多种实体瘤的活性,其作用机制可能与诱导细胞凋亡和促进细胞坏死有关。AIM: To investigate the activity of saxifragifolin B from Androsace umbellata against solid tumors.METHODS: Human hepatoma cell line BEL-7402,human lung adenocarcinoma epithelial cell line A549 and human gastric cancer cell line SGC7901 were treated with saxifragifolin B in vitro.Morphological changes of the tumor cells were observed under microscope.Cell deaths were determined by AO/EB double staining.Cell proliferation was assayed by MTT method.The IC50 values were graphically determined.Apoptosis and necrosis were measured by flow cytometry.RESULTS: Saxifragifolin B induced apoptosis and necrosis in all 3 tested solid tumor cells.Saxifragifolin B inhibited proliferation of tumor cells in a concentration-dependent manner with IC50 values of 13.13 μmol/L,9.61 μmol/L and 11.64 μmol/L at 24 h,respectively.Saxifragifolin B induced both apoptosis and necrosis in the tumor cells.CONCLUSION: Saxifragifolin B from Androsace umbellata has the activity against a variety of solid tumors with the possible mechanisms of inducing both apoptosis and necrosis.
关 键 词:点地梅 Saxifragifolin B BEL-7402细胞 A549细胞 SGC7901细胞
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.229